– October 1, 2003
October 1, 2003
View Issues
-
After 16 Years: ‘Watch and Wait’ No Different than Immediate Therapy for Favorable Histology Lymphoma
Currently, there is no curative treatment for advanced-stage, low-grade non-Hodgkins lymphoma, and there remains a question of when to initiate treatment in the asymptomatic patient. -
Port-Site Metastasis After Laparoscopic Surgery for Ovarian Cancer
Port-site metastasis after laparoscopic surgery during chemotherapy, or when adequate chemotherapy has been given, is usually associated with poor outcome. -
Postmastectomy Lymphedema: Laser Treatments May be the Answer for Some
Postmastectomy lymphedema remains a significant cause of morbidity for breast cancer patients, affecting up to 30% of patients who have received axillary node dissections and adjunctive radiotherapy. -
CNS Lymphoma and Thrombosis
Although a high incidence of thrombotic events is reported for primary brain tumors, the incidence in patients with CNS lymphoma is previously unreported. -
Phase II Study of Capecitabine and Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
Combining capecitabine and oxaliplatin yields promising activity in advanced colorectal cancer; therefore, the capecitabine dose we used is probably too high. The main toxicity is diarrhea, which is manageable with appropriate dose reductions. -
Intraperitoneal Radioactive Phosphorus (32P) vs Observation After Negative Second-Look Laparotomy for Stage III Ovarian Carcinoma
Intraperitoneal chromic phosphate did not decrease the risk of relapse or improve survival for patients with stage III epithelial ovarian cancer after a negative second-look surgery. -
Pharmacology Watch: Vardenafil Will Compete for Share of ED Market
The FDA has approved vardenafil (LevitraBayer and GlaxoSmithKline) for the treatment of erectile dysfunction in men. Vardenafil joins sildenafil (Viagra) as the only 2 drugs approved for this indication in this country.